Experts’ Take: Dialogue on Hypertriglyceridemia
Release date: July 23, 2014
Expiration date: July 23, 2015
Estimated time to complete activity: 0.75 hours
Course viewing requirements:
PC: Internet Explorer (v6 or greater), Google Chrome, or Firefox
MAC: Safari or Firefox
Jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and Medtelligence, LLC
This activity is supported by an independent educational grant from Amarin Pharma Inc.
This activity has been designed to meet the educational needs of Clinical Endocrinologists, Diabetologists, Internists, Clinical Cardiologists, Geriatricians, Nurse Practitioners, Physician Assistants, Allied Health Professionals, and Diabetes Nurse Educators involved in the care of patients with hypertriglyceridemia.
After completing this activity, the participant should be better able to:
Harold E. Bays, MD, FTOS, FACE, FNLA
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Sergio Fazio, MD, PhD, FAAP, FASCI
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine
Director of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Medtelligence, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Harold Bays reports that he has received clinical research grant support from GlaxoSmithKline, Novo Nordisk A/S, and Orexigen Therapeutics, Inc., clinical research grant support and speaker honoraria from Amarin Corp., Eisai Inc., and Vivus, Inc., and clinical research grant support and consultant honoraria from AstraZeneca and Omthera Pharmaceuticals. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of prescription EPA to lower TG, CRP and other metabolic effects; and Naltrexone/Bupropion in weight management. Dr. Bays has an identified conflict of interest and it has been resolved accordingly. He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.
Dr. Sergio Fazio reports that he has received consultant honoraria from Amarin Corp., Kowa Pharmaceuticals America, Inc., Hoffman-LaRoche, and sanofi-aventis US LLC, clinical trial institutional support from Amgen, Inc., ISIS Pharmaceuticals, Inc., and Pfizer Inc., and clinical trial institutional support and consultant honoraria from Merck & Co., Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fazio has an identified conflict of interest and it has been resolved accordingly. He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Medtelligence, LLC: Ben Caref, PhD; Pamela Clark - No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
There are no fees for participating and receiving CME credit for this activity. During the period July 23, 2014 through July 23, 2015, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID #10127. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|After viewing the program, return to this page to access the CME test||Use ID #10127|